Charles Schwab Investment Management Inc Zentalis Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $519 Billion
- Q2 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 468,413 shares of ZNTL stock, worth $1.78 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
468,413
Previous 455,937
2.74%
Holding current value
$1.78 Million
Previous $7.19 Million
73.35%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ZNTL
# of Institutions
146Shares Held
69.9MCall Options Held
61.8KPut Options Held
6.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$53.2 Million0.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$32.6 Million0.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.65MShares$21.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$18.4 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.5MShares$17.2 Million0.0% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $217M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...